

Sea Urchin Pigments as Potential Therapeutic Agents Against the Spike Protein of SARS-CoV-2 Based on in Silico Analysis

Elena Susana Barbieri, Tamara Rubilar, Ayelén Gázquez, Marisa Avaro, Erina Noé Seiler, Mercedes Vera-Piombo, Agustín Gittardi, Florencia Chaar, Jimena Pía Fernandez, Lucas Sepulveda

Submitted date: 26/06/2020 • Posted date: 29/06/2020

Licence: CC BY-NC-ND 4.0

Citation information: Barbieri, Elena Susana; Rubilar, Tamara; Gázquez, Ayelén; Avaro, Marisa; Seiler, Erina Noé; Vera-Piombo, Mercedes; et al. (2020): Sea Urchin Pigments as Potential Therapeutic Agents Against the Spike Protein of SARS-CoV-2 Based on in Silico Analysis. ChemRxiv. Preprint.

<https://doi.org/10.26434/chemrxiv.12568595.v1>

Several studies have been published regarding the interaction between the spike protein of the novel coronavirus SARS-CoV-2 and ACE2 receptor in the host cells. In the presente work, we evaluated the in silico properties of two sea urchin pigments, Echinochrome A (EchA) and Spinochromes (SpinA) against the Spike protein (S) towards finding a potential therapeutic drug against the disease caused by the novel coronavirus (COVID-19). The best ensemble docking pose of EchaA and SpinA showed a binding affinity of -5.9 and -6.7 kcal mol⁻¹, respectively. The linked aminoacids (T505, G496 and Y449 for EchA and Y449, Q493 and G496 for SpinA) are in positions involved in ACE2 binding in both RBDs frim SARS-CoV and SARS-CoV-2 suggesting that EchA and SpinA may interact with Spike proteins drom both viruses. The results suggest that these pigments could act as inhibitors of S protein, pointing them as antiviral drugs for SARS-CoV-2.

File list (5)

Fig_2B_Spike_RBM_SpinA.pdf (88.37 KiB)	view on ChemRxiv • download file
Barbieri et al_PreprintSpike_2020.pdf (288.13 KiB)	view on ChemRxiv • download file
Fig_2A_Spike_RBM_EchA.pdf (87.25 KiB)	view on ChemRxiv • download file
Fig_1B_Spike_RBM_SpinA.pdf (85.58 KiB)	view on ChemRxiv • download file
Fig_1A_Spike_RBM_EchA.pdf (85.69 KiB)	view on ChemRxiv • download file

Fig_2B_Spike_RBM_SpinA.pdf (88.37 KiB)

[view on ChemRxiv](#) • [download file](#)

1 ***Sea urchin pigments as potential therapeutic agents against the spike protein***
2 ***of SARS-CoV-2 based on in silico analysis.***

3
4
5 Barbieri Elena S.^{2,3*}^a, Rubilar Tamara^{1,3*}, Gázquez Ayelén⁴, Avaro Marisa¹, Seiler, Erina
6 Noé^{2,3}, Vera-Piombo Mercedes^{1,3}, Gittardi Agustín¹, Chaar, Florencia¹, Fernández Jimena
7 Pia^{1,3}, Sepúlveda Lucas^{1,3}

8
9
10 **Both authors contributed equally to the manuscript*

11 ¹ *Laboratorio de Química de Organismos Marinos - Instituto Patagónico del Mar-UNPSJB, Puerto*
12 *Madryn, Chubut, Argentina*

13 ² *Laboratorio de Virología - Instituto Patagónico del Mar-UNPSJB, Puerto Madryn, Chubut, Argentina*

14 ³ *Laboratorio de Oceanografía Biológica – CESIMAR -CONICET, Puerto Madryn, Chubut, Argentina*

15 ⁴ *Instituto Tecnológico de Chascomú, InTeCh – CONICET, Chascomús, Buenos Aires, Argentina*

16
17
18 a- **Corresponding author** barbieri@cenpat-conicet.gob.ar - elesuba14@gmail.com

19 Postal address: Boulevard Brown 2915, Puerto Madryn (9120), Chubut, Argentina.

20
21
22 **Abstract**

23 In the last few months, several studies have been published regarding the interaction between
24 the Spike protein of the novel coronavirus SARS-CoV-2 and ACE2 receptor in the host cells.
25 In the present work, we evaluated the *in silico* properties of two sea urchin pigments,
26 Echinochrome A (EchA) and Spinochromes (Spin A) against Spike protein (S) towards finding
27 a potential therapeutic drug against the disease caused by the novel coronavirus (COVID-19).
28 The best ensemble docking pose of EchA and SpinA showed a binding affinity of -5.9 and -6.7
29 kcal mol⁻¹, respectively. The linked aminoacids (Y505, G496 and Y449 for EchA and Y449,
30 Q498, Q493 and G496 for SpinA), are in positions involved in ACE2 binding in both RBDs
31 from SARS-CoV and SARS-CoV-2 suggesting that EchA and SpinA may interact with Spike
32 proteins from both viruses. The results suggest that these pigments could act as inhibitors of S
33 protein, pointing them as antiviral drugs for SARS-Cov-2. Since this study is performed
34 computationally, it requires *in vitro* and *in vivo* experiments for further validation.

35
36 **Keywords:** 2019 pandemic, 1,4-naphtoquinones polihydroxilate, Echinochrome A,
37 Spinochromes, antiviral drug.
38

39 **Introduction**

40

41 Coronaviruses include a wide range of hosts that infect mammalian and avian species. These
42 viruses comprise a large and diverse family of enveloped, positive-stranded RNA viruses.
43 Worldwide, three betacoronaviruses have crossed the species barrier and produced deadly
44 pneumonia in humans. Despite this, the infection by human coronavirus was not considered
45 serious to be controlled by vaccination or to devise specific antivirals until the emergence of
46 severe acute respiratory syndrome (SARS) in 2003 (De Clercq, 2004). Two strains of SARS
47 have generated epidemics: severe acute respiratory syndrome coronavirus (SARS-CoV) and,
48 Middle-East respiratory syndrome coronavirus (MERS-CoV), but it is the current strain that is
49 globally important as a pandemic situation (SARS-CoV-2).

50

51 The SARS-CoV-2 disease, COVID-19, has already cost near 479K lives and more than 9
52 million people are positive confirmed all over the world (<https://covid19.who.int/>, June 25th
53 2020). This pandemic is evidence of the potential of coronaviruses to continuously evolve in
54 wild reservoirs and jump to new species (Jaimes et al., 2020).

55

56 In this global scenario, there is an urgent requirement for a specific antiviral drug against virus
57 infection and finding the most efficient antiviral drugs available to treat or prevent the disease
58 concerned. New demands for antiviral strategies have increased markedly. The lack of available
59 therapies and vaccines for COVID-19 treatment has led to use of several unsuccessful
60 treatments from drug repositioning of antivirals unable to prevent the death or recovery of
61 patients who ended up with serious lung and heart failures (Guan et al., 2020; Wang et al., 2020;
62 Xu et al., 2020; Zheng et al., 2020; Wang et al., 2020).

63

64 The huge variations in host range and tissue tropism among coronaviruses are largely
65 attributable to changes in the homotrimeric spike glycoprotein, liable for binding to the cellular
66 receptors. The spike protein (S) that protrudes from the envelope of the virion, becomes a
67 potential target for vaccines and therapeutic design, as it mediates viral entry into host cells and
68 membrane fusion (Li, 2016; Tortorici et al., 2019). Spike residues in the viral envelope are
69 responsible for membrane fusion by engaging angiotensin-converting enzyme 2 (ACE2)
70 receptors. ACE2 is found in the heart, lungs, kidney, endothelium, and intestine (Chen et al.,
71 2020; Zhang et al., 2020). Protein S, a trimeric class I fusion protein, is composed of two
72 subunits, S1 (which contains a receptor binding domain or RBD), responsible for binding to the

73 ACE2 receptor on the host cell and S2 (which mediates viral-membrane fusion through the
74 exposure of a highly conserved fusion peptide). Analysis of experimental structures of the
75 SARS-CoV-2 S protein RBD in complex with ACE2 showed that this interface represents an
76 active area of research for therapeutic development (Zhang et al., 2020). Residues on RBD in
77 S protein, essential for ACE2 binding, are highly conserved or share similar side chain
78 properties between SARS-CoV and SARS-Cov-2 which indicate convergent evolution between
79 both RBDs, for improved binding to ACE2 (Lan et al., 2020).

80

81 Until date no treatment has been effective in any of these strategies. In order to interfere with
82 key protein required for viral entry into cells and to neutralize essential proteins in viral
83 replication, molecules capable of reaching strategic binding-sites that sometimes are
84 inaccessible to others, are needed. For example, to prevent the virus from entering the cell it is
85 necessary to avoid the successful union of the S protein and the ACE2 receptor by using small
86 molecules (Zhang et al., 2020). The binding of potential small molecules to spike protein can
87 possibly inhibit the replication and transcription of the virus (Rout et al., 2020). In addition to
88 different drug compounds, researchers also look for natural molecules having antiviral activity
89 (Rout et al., 2020).

90

91 Among the small molecules, sea urchin pigments are a very interesting group of bioactive
92 compounds that not only have antiviral and antibacterial properties but also reduce ROS stress
93 (Cirino et al., 2017; Fedoreyev et al., 2018). One of the relevant families of sea urchin pigments
94 is 1,4-naphtoquinones polihydroxilate (PHNQs), which includes Spinochrome A and
95 Echinochrome A (Cirino et al., 2017; Fedoreyev et al., 2018; Hou et al., 2020; Vasileva et al.,
96 2017). Specifically, Echinochrome A (EchA) is the active compound of HistoChrome® and
97 GistoChrome® (xx), two Russian preparations for cardiopathies and glaucoma diseases that
98 reached the pharmaceutical market and passed all the regulatory requirements. Due to their
99 particular molecular structure, PHNQs pigments possess important antioxidant actions,
100 although their antimicrobial, anti-inflammatory, ion chelating, antiallergic, antidiabetic,
101 antihypertensive, cardioprotective and hypocholesterolemic properties are also highlighted
102 (Jeong et al., 2014; Lebedev et al., 2005; Lennikov et al., 2014; Shikov et al., 2018). The
103 pharmacological activity observed in patients with various alignments, together with the
104 identified low toxicity profiles, strongly support the potential and therapeutic benefits of these
105 natural pigments for the treatment of various human diseases, particularly inflammation, cardio-
106 protection and diabetes (Shikov et al., 2018). One of the computational tools, molecular

107 docking, has gained attention as an essential one to investigate potential inhibitor molecules
108 (Rout et al., 2020).

109

110 Hence, considering the urgent requirement for a specific antiviral drug, this study aims to
111 examine the *in silico* properties of EchA and SpinA against Spike protein of SARS-CoV-2, and
112 in this way, suggest a potential therapeutic drug especially against COVID-19, and other
113 coronaviruses as well.

114

115

116 **Materials and Methods**

117

118 *In silico* study was performed to evaluate the interaction between Echinochrome A (EchA) and
119 Spinochrome A (SpinA) against the viral glycoprotein Spike.

120

121 The receptor preparation was done according to Forli et al. (Forli et al., 2016) with a few
122 modifications. SARS-CoV-2 receptor-binding domain (RBD) of the Spike protein co-
123 crystalized with ACE2 (6M0J, resolution 2.45 Å) was downloaded from RCSB
124 (<https://www.rcsb.org/>). Water and ligand molecules were removed from the file and the
125 software AutoDockTools (ADT version 1.5.7) was used for receptor preparation. Polar
126 hydrogens were added and partial Kollman charges were assigned. The prepared structures
127 were individually saved in .pdbqt format.

128

129 The SMILE of EchA and SpinA were downloaded from Chemical Entities of Biological Interest
130 (ChEBI) and PubChem (<https://pubchem.ncbi.nlm.nih.gov/>) and, transformed to PDB.

131

132 The docking simulations were performed using AutoDock vina 1.1.2 (Trott and Olson, 2010).
133 The center of the search space size for Spike protein docking (-29.04, 30.288, 7.61;
134 37.50x47.25x46.50 Å) were set to cover the receptor-binding motif (Lan et al., 2020).

135 The exhaustiveness has been set to 24 while remaining of AutoDock Vina parameters have
136 been kept at default values. The results of the docking experiment were ranked according to
137 their Vina score and docking poses were visually inspected with UCSF Chimera software
138 (Pettersen et al., 2004). The top ranked candidates were selected for further analysis of protein-
139 ligand interactions. Hydrogen bonds (H-bonds) were detected with UCSF Chimera relax H-
140 bonds constraints (0.5 Å and 25°). All direct interactions were also identify as clashes and

141 contact. Note that clashes are unfavorable interactions where atoms are too close together while
142 contacts denote all kinds of direct interactions (polar and nonpolar, favorable and unfavorable)
143 including clashes.

144

145

146 **Results and discussion**

147

148 The auto dock software was used for molecular docking analyses of EchA and SpinA against
149 the receptor-binding domain (RBD) complex of the spike protein. The docking consisted of
150 positioning ligands (EchA and SpinA) into the active site and predict how aminoacids will
151 interact in the binding site of the receptor. This technique helps to enhance the success rate of
152 an experiment and cuts down the experimental cost. The molecular docking study can help to
153 analyze the possible binding pose of a small molecule on the active site of a macromolecule
154 (Rout et al., 2020).

155

156 The best ensemble docking pose of EchA and SpinA showed a binding affinity of -5.9 and -6.7
157 kcal mol⁻¹, respectively. These Vina docking scores indicate the stability of the complex for
158 both urchin pigment molecules.

159

160 Phylogenetic analysis of RBD showed a similarity between SARS-CoV and SARS-CoV-2 (five
161 out of six hotspot aminoacids in SARS-CoV-2 have their equivalent in SARS-CoV) and the
162 importance of the linked-aminoacids in it (Othman et al., 2020). Computer modelling of the
163 interaction between the SARS-CoV-2 RBD and ACE2 has identified some residues potentially
164 involved in this interaction (Lan et al., 2020). Our molecular docking analyses showed that
165 EchA and SpinA formed hydrogen bonds with different aminoacids residing on the RBD of the
166 Spike protein (Fig. 1).

167

168 In particular, the interaction between Spike and EchA (Fig. 2-A) showed three H-bonds with
169 Y449 and Q498 (in green), and 32 Van der Walls (VdW) contacts with R403, S494, Q498,
170 Q493, Y449, Y505, G496, Y495 (in orange), and no clashes. On the other hand, SpinA (Fig. 2-
171 B) showed five H-bonds interacted with R403, Y449, Q498, Q493 and S494. Besides, 32 VdW
172 contacts with Q493, Q498, Y495, R403, S494, Y449 and G496, with no clashes. It is important
173 to mention that linked-aminoacids –i.e., Y449, Q498, Q493, Y505, and G496- are part of the
174 receptor-binding motif (RBM) that interacts directly with ACE2 (Lan et al., 2020).

175 With regard to the linked aminoacids (Y505, G496 and Y449 for EchA and Y449, Q498, Q493
176 and G496 for SpinA), they are in positions involved in ACE2 binding in both RBDs from SARS
177 CoV and SARS CoV 2 suggesting that EchA and SpinA may interact with Spike proteins from
178 both viruses. From this, we suggest that these sea urchin pigments could become possible
179 antiviral drugs because they may interfere with viral infection through binding to Spike
180 glycoprotein with particular interest for experimental evaluation. Actually, there is an urgent
181 need for secure and effective therapeutic options for SARS-CoV-2 infections; in particular,
182 there is no approved therapy for COVID-19. Taking into account the results obtained in this *in*
183 *silico* study, we propose an in vitro analysis for evaluating the effect of these two small natural
184 molecules in coronavirus inhibition. Especially EchA is a natural compound already available
185 for other illnesses, and neither toxicity at test concentration nor adverse reactions were found;
186 in addition, all the clinical regulations have been approved. The results showed in this study are
187 part of a provisional patent under revision.

188

189

190 **Conclusion**

191

192 Our results suggest that sea urchin pigments, EchA and SpinA, could act as inhibitors of S
193 protein, pointing them as antiviral drugs for SARS-Cov-2.

194

195 **References**

196

197 Chen, L., Li, X., Chen, M., Feng, Y., Xiong, C., 2020. The ACE2 expression in human heart
198 indicates new potential mechanism of heart injury among patients infected with SARS-CoV-
199 2. *Cardiovasc. Res.* <https://doi.org/10.1093/cvr/cvaa078>

200 Cirino, P., Brunet, C., Ciaravolo, M., Galasso, C., Musco, L., Fernández, T.V., Sansone, C.,
201 Toscano, A., 2017. The sea urchin *arbia* *lixula*: A novel natural source of astaxanthin.
202 *Mar. Drugs.* <https://doi.org/10.3390/md15060187>

203 De Clercq, E., 2004. Antivirals and antiviral strategies. *Nat. Rev. Microbiol.* 2, 704–720.
204 <https://doi.org/10.1038/nrmicro975>

205 Fedoreyev, S.A., Krylova, N. V., Mishchenko, N.P., Vasileva, E.A., Pislyagin, E.A., Iunikhina,
206 O. V., Lavrov, V.F., Svitich, O.A., Ebralidze, L.K., Leonova, G.N., 2018. Antiviral and
207 antioxidant properties of echinochrome A. *Mar. Drugs* 16, 1–10.
208 <https://doi.org/10.3390/md16120509>

209 Forli, S., Huey, R., Pique, M.E., Sanner, M.F., Goodsell, D.S., Olson, A.J., 2016. Computational
210 protein-ligand docking and virtual drug screening with the AutoDock suite. *Nat. Protoc.*
211 <https://doi.org/10.1038/nprot.2016.051>

212 Guan, W., Ni, Z., Hu, Y., Liang, W., Ou, C., He, J., Liu, L., Shan, H., Lei, C., Hui, D.S.C., Du,
213 B., Li, L., Zeng, G., Yuen, K.Y., Chen, R., Tang, C., Wang, T., Chen, P., Xiang, J., Li, S.,
214 Wang, J.L., Liang, Z., Peng, Y., Wei, L., Liu, Y., Hu, Y.H., Peng, P., Wang, J.M., Liu, J.,
215 Chen, Z., Li, G., Zheng, Z., Qiu, S., Luo, J., Ye, C., Zhu, S., Zhong, N., 2020. Clinical
216 characteristics of coronavirus disease 2019 in China. *N. Engl. J. Med.* 382, 1708–1720.
217 <https://doi.org/10.1056/NEJMoa2002032>

218 Hou, Y., Carne, A., McConnell, M., Bekhit, A.A., Mros, S., Amagase, K., Bekhit, A.E.D.A.,
219 2020. In vitro antioxidant and antimicrobial activities, and in vivo anti-inflammatory activity
220 of crude and fractionated PHNQs from sea urchin (*Evechinus chloroticus*). *Food Chem.*
221 <https://doi.org/10.1016/j.foodchem.2020.126339>

222 Jaimes, J.A., André, N.M., Chappie, J.S., Millet, J.K., Whittaker, G.R., 2020. Phylogenetic
223 Analysis and Structural Modeling of SARS-CoV-2 Spike Protein Reveals an Evolutionary
224 Distinct and Proteolytically Sensitive Activation Loop. *J. Mol. Biol.* 432, 3309–3325.
225 <https://doi.org/10.1016/j.jmb.2020.04.009>

226 Jeong, S.H., Kim, H.K., Song, I.S., Lee, S.J., Ko, K.S., Rhee, B.D., Kim, N., Mishchenko, N.P.,
227 Fedoryev, S.A., Stonik, V.A., Han, J., 2014. Echinochrome a protects mitochondrial
228 function in cardiomyocytes against cardiotoxic drugs. *Mar. Drugs.*
229 <https://doi.org/10.3390/md12052922>

230 Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., Wang,
231 X., 2020. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2
232 receptor. *Nature* 581, 215–220. <https://doi.org/10.1038/s41586-020-2180-5>

233 Lebedev, A. V., Ivanova, M. V., Levitsky, D.O., 2005. Echinochrome, a naturally occurring iron
234 chelator and free radical scavenger in artificial and natural membrane systems. *Life Sci.*
235 <https://doi.org/10.1016/j.lfs.2004.10.007>

236 Lennikov, A., Kitaichi, N., Noda, K., Mizuuchi, K., Ando, R., Dong, Z., Fukuhara, J., Kinoshita,
237 S., Namba, K., Ohno, S., Ishida, S., 2014. Amelioration of endotoxin-induced uveitis treated
238 with the sea urchin pigment echinochrome in rats. *Mol. Vis.*

239 Li, F., 2016. Structure, Function, and Evolution of Coronavirus Spike Proteins. *Annu. Rev. Virol.*
240 <https://doi.org/10.1146/annurev-virology-110615-042301>

241 Othman, H., Bouzlama, Z., Brandenburg, J.T., da Rocha, J., Hamdi, Y., Ghedira, K., Srairi-Abid,
242 N., Hazelhurst, S., 2020. Interaction of the spike protein RBD from SARS-CoV-2 with
243 ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor
244 polymorphism. *Biochem. Biophys. Res. Commun.* 527, 702–708.
245 <https://doi.org/10.1016/j.bbrc.2020.05.028>

246 Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., Ferrin,
247 T.E., 2004. UCSF Chimera - A visualization system for exploratory research and analysis.
248 *J. Comput. Chem.* <https://doi.org/10.1002/jcc.20084>

249 Rout, J., Swain, C., Tripathy, U., 2020. In Silico Investigation of Spice Molecules as Potent
250 Inhibitor of SARS-CoV-2. Chemrxiv. <https://doi.org/10.26434/chemrxiv.12089730.v1>
251 Scope

252 Shikov, A.N., Pozharitskaya, O.N., Krishtopina, A.S., Makarov, V.G., 2018. Naphthoquinone
253 pigments from sea urchins: chemistry and pharmacology. *Phytochem. Rev.*
254 <https://doi.org/10.1007/s11101-018-9547-3>

255 Tortorici, M.A., Walls, A.C., Lang, Y., Wang, C., Li, Z., Koerhuis, D., Boons, G.J., Bosch, B.J.,
256 Rey, F.A., de Groot, R.J., Veesler, D., 2019. Structural basis for human coronavirus
257 attachment to sialic acid receptors. *Nat. Struct. Mol. Biol.* <https://doi.org/10.1038/s41594-019-0233-y>
258

259 Trott, O., Olson, A.J., 2010. AutoDock Vina: Improving the Speed and Accuracy of Docking with
260 a New Scoring Function, Efficient Optimization, and Multithreading. *J. Comput. Chem.* 31,
261 455–461. <https://doi.org/10.1002/jcc>

262 Vasileva, E.A., Mishchenko, N.P., Fedoreyev, S.A., 2017. Diversity of
263 Polyhydroxynaphthoquinone Pigments in North Pacific Sea Urchins. *Chem. Biodivers.*
264 <https://doi.org/10.1002/cbdv.201700182>

265 Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y.,
266 Zhao, Y., Li, Y., Wang, X., Peng, Z., 2020. Clinical Characteristics of 138 Hospitalized
267 Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA - J.*
268 *Am. Med. Assoc.* <https://doi.org/10.1001/jama.2020.1585>

269 Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L.,
270 Tai, Y., Bai, C., Gao, T., Song, J., Xia, P., Dong, J., Zhao, J., Wang, F.S., 2020. Pathological
271 findings of COVID-19 associated with acute respiratory distress syndrome. *Lancet Respir.*
272 *Med.* 8, 420–422. [https://doi.org/10.1016/S2213-2600\(20\)30076-X](https://doi.org/10.1016/S2213-2600(20)30076-X)

273 Zhang, H., Penninger, J.M., Li, Y., Zhong, N., Slutsky, A.S., 2020. Angiotensin-converting
274 enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential
275 therapeutic target. *Intensive Care Med.* <https://doi.org/10.1007/s00134-020-05985-9>


276 Zheng, Y.Y., Ma, Y.T., Zhang, J.Y., Xie, X., 2020. COVID-19 and the cardiovascular system.
277 *Nat. Rev. Cardiol.* 17, 259–260. <https://doi.org/10.1038/s41569-020-0360-5>
278
279

280 **Figure caption**

281 Figure 1. SARS-CoV-2 RBD Spike protein interaction with urchin pigments. (A)
282 Structure of SARS-CoV-2 RBD Spike bound to EchA best docking pose. EchA is shown
283 in green, SARS-CoV-2 RBD Spike core is shown in blue and the RBM is shown in red.
284 (B) Structure of SARS-CoV-2 RBD Spike bound to SpinA best docking pose. SpinA is
285 shown in green, SARS-CoV-2 RBD Spike core is shown in blue and the RBM is shown
286 in red.

287

288 **A**




289

290

291

292 **B**

293



294


295

296 Figure 2. Details of H-bonds and Van der Waals interactions between urchin pigments
297 and RBD. (A) Analyzed interactions between EchA best docking pose and SARS-CoV-
298 2 RBD and (B) Analyzed interactions between SpinA best docking pose and SARS-CoV-
299 2 RBD. The H-bonds are highlighted in green, and VdW interactions in orange. Main
300 amino acids participating on the interactions are labeled.

301

302 **A**

303



304


305

306

307

308 **B**

309




310

311

312


Barbieri et al_PreprintSpike_2020.pdf (288.13 KiB)

[view on ChemRxiv](#) • [download file](#)




Fig_2A_Spike_RBM_EchA.pdf (87.25 KiB)

[view on ChemRxiv](#) • [download file](#)



Fig_1B_Spike_RBM_SpinA.pdf (85.58 KiB)

[view on ChemRxiv](#) • [download file](#)



Fig_1A_Spike_RBM_EchA.pdf (85.69 KiB)

[view on ChemRxiv](#) • [download file](#)
